Adenocarcinoma of the Stomach Clinical Trial
Official title:
Anti-EGFR Antibody (GC-1118) in Combination With Weekly Paclitaxel as a Second-line Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas With Amplifications
Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.
Participants will receive each treatment if the gastric cancer tissue sample reveals either EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00982592 -
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
| Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00098527 -
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03647969 -
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Terminated |
NCT00871273 -
Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma
|
Phase 4 | |
| Recruiting |
NCT05729646 -
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT05315830 -
A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric
|
Phase 1 | |
| Recruiting |
NCT06299163 -
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT01095120 -
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
|
Phase 2 | |
| Completed |
NCT00062374 -
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
|
Phase 2 | |
| Not yet recruiting |
NCT05970627 -
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT02202759 -
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction
|
Phase 2 | |
| Recruiting |
NCT01962519 -
Early Oral Feeding After Total Gastrectomy for Cancer
|
N/A | |
| Completed |
NCT00607594 -
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
|
Phase 2 | |
| Recruiting |
NCT06121700 -
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
|
Phase 2 | |
| Terminated |
NCT03722108 -
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05715931 -
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT02678182 -
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
|
Phase 2 | |
| Completed |
NCT01640782 -
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach
|
Phase 3 | |
| Recruiting |
NCT05872685 -
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
|
Phase 2 |